en · de · es · fr · pt
hplc-notes.peptides4088.com › Guide › Background And Molecular Identity — 2026 Update

Background And Molecular Identity — 2026 Update

By Editorial Desk · published 2026-04-01 · last reviewed 2026-04-26 · Guide

The short version of thymalfasin fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-04-26. Anything still debated is marked as such rather than presented as settled.

Background and Molecular Identity

The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.

Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.

Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.

Background, Structure, and Mechanism

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular massAbout 3.1 kDa28 residues, N-terminally acetylated
AppearanceWhite to off-white powderLyophilized solid
SolubilityFreely soluble in waterAlso soluble in aqueous buffers
Storage temperature2 to 8 °CProtect from light and moisture
Common synonymsThymalfasin; Tα1Same peptide sequence

Molecular Background and Immune Action

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Related pages on this site

Background and Molecular Profile

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

分子身份与天然来源

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

Further detail

Cirrhosis can take quite a long time to develop, and symptoms may be slow to emerge. Some early symptoms include tiredness, weakness, loss of appetite, weight loss, and nausea. Early signs may also include redness on the palms known as palmar erythema. People may also feel discomfort in the right upper abdomen around the liver. As cirrhosis progresses, symptoms may include neurological changes affecting both the peripheral and central nervous systems, disrupting the neurotransmission within the brain and causing neuromuscular fatigue. This can consist of cognitive impairments, confusion, memory loss, sleep disorders, and personality changes. Steatorrhea or presence of undigested fats in stool is also a symptom of cirrhosis. Worsening cirrhosis can cause a build-up of fluid in different parts of the body, such as the legs (edema) and abdomen (ascites). Other signs of advancing disease include itchy skin, bruising easily, dark urine, and yellowing of the skin.

== Radiolabeled somatostatin receptor antagonists in Peptide Radionuclide Receptor Therapy (PRRT) == Somatostatin receptor antagonists are also being developed as therapeutic agents in peptide radionuclide receptor therapy (PRRT) due to the wider binding of antagonists compared to agonists. Research indicated the antagonist Lu-DOTA-JR11 showed higher tumor uptake, more double-strand breaks within tumor cells, longer adherence time to tumors and improved tumor-to-kidney dose ratio. Moreover, another study finds out that radioactive atom, terbium-161 (161Tb), that can release short-ranged electrons, can combine with somatostatin receptor antagonists which localize at the cell membrane, giving an alternative solution, rather than the currently clinically used lutetium-somatostatin receptor agonist, which localize at the cytoplasm and nucleus. Moreover, Tb-antagonist in vitro shows 102-fold more potent than Lu-antagonist in inhibiting tumor cell growth and prolonging survival of mice, which is trusted to be due to its high linear energy transfer. This result is further repeated and confirmed in vivo, showing the high potential and strengths of radiolabeled somatostatin receptor antagonists to treat neuroendocrine neoplasms.

The Special Air Service (SAS) is a special forces unit of the British Army. It was founded as a regiment in 1941 by David Stirling, and in 1950 it was reconstituted as a corps. The unit specialises in a number of roles including counter-terrorism, hostage rescue, direct action and special reconnaissance. Much of the information about the SAS is highly classified, and the unit is not commented on by either the British government or the Ministry of Defence due to the secrecy and sensitivity of its operations. The corps consists of the 22 Special Air Service Regiment, which is the regular component, as well as the 21 Special Air Service Regiment (Artists) (Reserve) and the 23 Special Air Service Regiment (Reserve), which are reserve units, all under the operational command of United Kingdom Special Forces (UKSF). Its sister unit is the Royal Navy's Special Boat Service, which specialises in maritime counter-terrorism. Both units are under the operational control of the Director Special Forces. The Special Air Service traces its origins to 1941 during the Second World War. It was reformed as part of the Territorial Army in 1947, named the 21st Special Air Service Regiment (Artists Rifles). The 22nd Special Air Service Regiment, which is part of the regular army, gained fame and recognition worldwide after its televised rescue of all but two of the hostages held during the 1980 Iranian Embassy siege.

Glutathione peroxidase 1, also known as GPx1, is an enzyme that in humans is encoded by the GPX1 gene on chromosome 3. This gene encodes a member of the glutathione peroxidase family. Glutathione peroxidase functions in the detoxification of hydrogen peroxide, and is one of the most important antioxidant enzymes in humans.

==== MeSH E05.393.183 – chromosome mapping ==== MeSH E05.393.183.250 – chromosome walking MeSH E05.393.183.620 – physical chromosome mapping MeSH E05.393.183.620.160 – contig mapping MeSH E05.393.183.620.405 – radiation hybrid mapping MeSH E05.393.183.620.650 – restriction mapping

Sources: en.wikipedia.org

Supporting material

== Medical uses == Vancomycin is indicated for the treatment of serious, life-threatening infections by Gram-positive bacteria of both aerobic and anaerobic types that are unresponsive to other antibiotics. The increasing emergence of vancomycin-resistant enterococci (VRE) has resulted in the development of guidelines for use by the Centers for Disease Control Hospital Infection Control Practices Advisory Committee. These guidelines restrict use of vancomycin to these indications:

The C-terminal domain has structural similarities to the serum protein hemopexin. It has a four-bladed β-propeller structure. β-Propeller structures provide a large flat surface that is thought to be involved in protein-protein interactions. This determines substrate specificity and is the site for interaction with TIMP's (tissue inhibitor of metalloproteinases). The hemopexin-like domain is absent in MMP-7, MMP-23, MMP-26, and the plant and nematode. The membrane-bound MMPs (MT-MMPs) are anchored to the plasma membrane via a transmembrane or a GPI-anchoring domain.

Buspirone was developed in 1968 and approved for medical use in the United States in 1986. It is available as a generic medication. In 2023, it was the 40th most commonly prescribed medication in the United States, with more than 15 million prescriptions.

Duterte campaigned to eliminate illegal drugs in the country within three to six months, but later acknowledged he miscalculated the severity of the problem as he based his approach to that of Davao City during his tenure as the city's mayor. Stating it would take him his entire term to eradicate it, he cited the difficulty in border control due to the country's fragmented geography and lamented that several government officials and law enforcers were involved in drug trafficking. Before leaving office, he implored president-elect Bongbong Marcos to continue tackling the illegal drug problem, but declined an appointment offer as Marcos' drug czar, expressing a desire to retire. By the end of Duterte's term, the number of drug suspects killed since Duterte took office was officially tallied by the government as 6,252; human rights groups, however, claim drug casualties reached as high as 12,000 to 30,000. Various international publications and media companies had claimed that Duterte's anti-drugs campaign was a war against the poor due to the abject poverty of those arrested or killed. On June 19, 2018, 38 United Nations member states released a collective statement through the United Nations Human Rights Council, calling on the Philippines and Duterte to end the killings in the war on drugs and cooperate in investigating human rights abuses.

Sources: en.wikipedia.org

Supporting material

Beta-secretase 1, also known as beta-site amyloid precursor protein cleaving enzyme 1, beta-site APP cleaving enzyme 1 (BACE1), membrane-associated aspartic protease 2, memapsin-2, aspartyl protease 2, and ASP2, is an enzyme that in humans is encoded by the BACE1 gene. Expression of BACE1 is observed mainly in neurons and oligodendrocytes. BACE1 is an aspartic acid protease important in the formation of myelin sheaths in peripheral nerve cells: in mice the expression of BACE1 is high in the postnatal stages, when myelination occurs. The transmembrane protein contains two active site aspartate residues in its extracellular protein domain and may function as a dimer, its cytoplasmic tail is required for the correct maturation and an efficient intracellular trafficking, but does not affect the activity. It is produced as a pro-enzyme, the endoproteolitc removal occurs after BACE leaves endoplasmic reticulum, in the Golgi apparatus. In addition the pro-peptide receives additional sugars to increase the molecular mass. and the tail became a palmitoylated. The BACE1 expression is influenced by the inflammatory state: during AD the cytokines reduce the PPAR1 an inhibitor of BACE1 mRNA.

== History == Lebanon was officially established on April 30, 1830. It was named by a pioneer settler who saw a stand of hickory trees on the site and was reminded of the Biblical cedars of Lebanon. The first post office at Lebanon was established in 1832. In 1853, Lebanon was incorporated as a town and later became a city in 1875.

== Awards and honours == 2014 Royal Microscopical Society Life Sciences Medal 2014 Fellow of Royal Society of Biology 2018 Fellow of Royal Microscopical Society 2019 Biochemical Society Industry and Collaboration Award 2024 Fellow of the Academy of Medical Sciences

=== Historical cases === In 2000 an Australian mining company, South Blackwater Coal Ltd, with 400 employees, imposed drug-testing procedures. The trade unions advised their members to refuse to take the tests, partly because a positive result does not necessarily indicate present impairment. The workers were stood-down by the company without pay for a week. In 2003, sixteen members of the Chicago White Sox considered refusing to take a drug test, in hopes of making steroid testing mandatory. In 2006, Levy County, Florida, volunteer librarians resigned en masse rather than take drug tests. In 2010, Iranian super heavyweight class weightlifters refused to submit to a drug test authorized by the Iran Weightlifting League.

== History == In the Standard Model (SM), matter stability is described by assigning a baryon number B=+1 to the proton (lightest baryon), following Hermann Weyl's 1929 proposed conservation principle. Ernst Stueckelberg formally postulated the baryon number (heavy charge at the time) conservation law in 1939. In the 1950s it was realized that limits on proton decay were exceedingly long. The very existence of advanced life forms on Earth implied

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha-1?

It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.

Where does the name come from?

The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.

Is it the same as thymosin beta-4?

No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.

What is thymosin alpha-1 derived from?

It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.

Network